Akron Children's > For Families & Patients > Research > Pediatric Clinical Studies > Open Clinical Studies

Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Description:

For complete information, please view the study on clinicaltrials.gov.

This study is being done in collaboration with Cincinnati Children's Hospital.

Study Status:

Closed

Full IRB Study Title:

ADVL1513: A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

IRB Study ID:

1042403-1

If you are interested in this study or have questions about your child's eligibility, please contact:

Rebecca D. Considine Research Institute, 330-543-3193 or email research@akronchildrens.org

While we are ranked among the best children's hospitals in the country, it's our compassionate approach to treatment that makes us truly exceptional. Through a combination of revolutionary treatments and extraordinary patient experiences, our care does more than heal. It brings the entire family together for emotional support and understanding across multiple locations to reach you in the community where you live. Learn more...